Expects Exact Sciences (EXAS) acquisition to be immediately accretive to organic annual sales growth rates… Abbott (ABT): approximate +50 basis points; Abbott Diagnostics Segment: approximate +300 basis points. Immediately accretive to annual gross margin profile… Abbott: approximate +100 basis points; Abbott Diagnostics Segment: approximate +700 basis points. Expects at least $100M in annual pre-tax synergies by 2028. Sees acquisition dilutive to adjusted earnings per share through 2027… 2026: (20c); 2027: (16c). Abbott expects to return to double-digit EPS growth. 2028… Transaction expected to be accretive in 2028 and beyond. Financing… Transaction will be financed with a combination of cash on hand and debt financing. Abbott expects to maintain an investment grade credit-rating. Abbott expects an initial 2026 adjusted gross debt-to-EBITDA ratio of approximately 2.7x following the transaction close. Comments taken from investor presentation slides.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Laboratories to Acquire Exact Sciences for $21B
- Abbott to acquire Exact Sciences for $105 per share, or equity value ~$21B
- Exact Sciences jumps 17% to $100.98 after Abbott buyout offer
- Abbott Laboratories’ Strategic Acquisition of Exact Sciences Drives Buy Rating
- Mizuho says $100 per share takeout price for Exact Sciences ‘feasible’